中国实用外科杂志2024，Vol.44Issue(7)：733-736,4.DOI:10.19538/j.cjps.issn1005-2208.2024.07.03
《美国临床肿瘤学会晚期肝细胞癌系统治疗指南更新》解读
Interpretation on systemic therapy for advanced hepatocellular carcinoma:ASCO guideline update
摘要
Abstract
On March 19,2024,the American Society of Clinical Oncology(ASCO)released an update to the guidelines for the systemic treatment of advanced hepatocellular carcinoma(HCC).This update,based on eight phase Ⅲrandomized controlled trials(RCTs)from the 2020 ASCO guidelines,integrated ten latest RCT data in recent years and recommended atezolizumab plus bevacizumab or durvalumab plus tremelimumab as the preferred first-line treatment for advanced HCC patients with Child-Pugh A status and ECOG PS 0-1.It also addressed the selection of second-line and subsequent-line treatments for advanced HCC patients.关键词
晚期肝细胞癌/美国临床肿瘤学会/系统治疗Key words
advanced hepatocellular carcinoma/the Ameri-can Society of Clinical Oncology/systemic therapy分类
医药卫生引用本文复制引用
周睿,陈亚进..《美国临床肿瘤学会晚期肝细胞癌系统治疗指南更新》解读[J].中国实用外科杂志,2024,44(7):733-736,4.基金项目
国家自然科学基金项目(No.81972263) （No.81972263）
